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In the absence of speciﬁc surveillance platforms for pertussis and availability of suitable diagnostics at the hospital level, reliable data
that describe morbidity and mortality from pertussis are difﬁcult to obtain in any setting, as is the case in West Africa. Here, we sum-
marize the available evidence of the burden of pertussis in the region, given historical data, and describe recent and ongoing epidemi-
ological studies that offer opportunities for additional data collection. The available seroepidemiological data provide evidence of
ongoing circulation of Bordetella pertussis in the region. Due to the lack of systematic and targeted surveillance with laboratory con-
ﬁrmation of B. pertussis infection, we cannot deﬁnitively conclude that pertussis disease is well controlled in West Africa. However,
based on observations by clinicians and ongoing demographic surveillance systems that capture morbidity andmortality data in general
terms, currently there is no evidence that pertussis causes a signiﬁcant burden of disease in young children in West Africa.
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Despite the reported outbreaks of pertussis in high-income set-
tings over recent years, relatively little data are available from
West Africa to substantiate the World Health Organization’s es-
timated ﬁgures for morbidity and mortality in low- and middle-
income countries (LMICs) [1]. In West Africa, the current dis-
ease burden cannot be quantiﬁed accurately as no reliable and
consistent surveillance systems for pertussis are in place.
Nevertheless, epidemiological data were collected in Senegal
in the 1990s and, more recently, some epidemiological, seroepi-
demiological, and hospital-based data have been reported from
Senegal, the Gambia, and Niger. We subsequently refer to these,
albeit limited, settings as West Africa.
HISTORICAL DATA FROM SENEGAL
An active surveillance program for pertussis was implemented
in Senegal’s Niakhar community in the 1980s to mid-1990s,
with the aim of measuring the changes in pertussis incidence
before and after introduction of the whole cell pertussis vaccine
into that community [2]. More than 15 000 children aged <15
years were actively followed over a 13-year period. The results
showed a crude pertussis incidence before vaccination of 183
per 1000 child-years, with a 2.8% case-fatality rate (Table 1).
After introduction of the vaccination program, overall incidence
dropped by 27% after 3 years and by 46% after 6 years (Figure 1).
The data clearly indicate the high efﬁcacy of the whole cell vac-
cine on pertussis cases in the observed communities.
This surveillance activity was discontinued after 1996 and no
further follow-up information is available. However, recent
Senegalese population-based data reveal no cases of pertussis
disease in children aged <10 years (Dr A. Diallo, personal
communication).
HOSPITAL DATA FROM NIGER
A recently published, hospital-based study from Niger reported
results from the analysis of nasopharyngeal aspirates (NPAs)
from 324 children hospitalized with respiratory symptoms at
the National Hospital of Niamey [3]. The NPAs were tested
by both culture and polymerase chain reaction (PCR). Of the
305 samples included in the analysis, 34 (11.2%) were found
to be positive for pertussis on PCR; however, only a single sam-
ple was also positive on bacterial culture. The authors conclud-
ed that there was an overall pertussis prevalence of 8.2 cases/
1000 children in this highly selective population of hospitalized
children.
SEROEPIDEMIOLOGY IN THE GAMBIA AND
SENEGAL
Currently no program of pertussis-speciﬁc surveillance exists
in West Africa. Recently we conducted a large cross-sectional
seroepidemiological study in the Gambia [4]. We accessed
stored samples from more than 1000 individuals aged between
2 and 90 years and measured immunoglobulin (Ig)G-pertussis
toxin (PTx) using luminex xMAP technology [5]. IgG-PTx
concentrations have been widely used to assess the prevalence
of B. pertussis infections. Previous studies show that concentra-
tions of anti-PTx antibodies ≥62.5 and ≥125 EU/mL were
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evidence of a previous infection in the past 12 and 6 months,
respectively [6].
IgG-PTx geometric mean concentrations (GMCs) and their
95% conﬁdence intervals were calculated. The proportion sero-
positive (>20 EU/mL or ≥62.5 EU/mL) and GMCs were com-
pared based on age, sex, ethnic group, vaccination status, birth
order, and number of siblings per household using logistic and
linear regression.
The Expanded Programme of Immunization (EPI) in the
Gambia, as in most LMICs, includes a whole cell pertussis an-
tigen as part of the pentavalent vaccine (hepatitis B, Haemophi-
lus inﬂuenzae type b, diphtheria–pertussis–tetanus [DPT]).
Table 1. Pertussis Case Distribution and Incidence per Age and Sex, During Epidemic Years, Niakhar, Senegal, 1984–1996
Age
First Outbreak (1986) Second Outbreak (1990) Third Outbreak (1993)
Cases
No. of
PYR
Incidence per
1000 PYR
Cases
No. of
PYR
Incidence per
1000 PYR
Cases
No. of
PYR
Incidence per
1000 PYRNo. % No. % No. %
0–5 mo 97 7 582 166.6 68 6 557 122.1 38 4 575 66.1
6–23 mo 246 18 1443 170.5 144 12 1700 84.7 58 7 1598 36.3
2–4 y 492 35 2530 194.5 348 30 2850 122.1 241 27 2969 81.2
5–14 y 570 40 6481 88 612 52 7422 82.5 555 62 7811 71.1
Total (0–14 y) 1405 100 11 036 127.3 1172 100 12 529 93.5 892 100 12 953 68.9
Girls 721 5395 133.6 580 6093 95.2 462 6276 73.6
Boys 684 5641 121.3 592 6436 92.0 430 6677 64.4
Relative risk (girls/boys)
(95% confidence
interval)
1.1 (1.0, 1.2) 1.0 (.9, 1.2) 1.1 (1.0, 1.3)
Reproduced with permission from Preziosi et al [2].
Abbreviation: PYR, person-years at risk.
Figure 1. Pertussis cases per month, vaccine uptake and age-specific vaccine coverage per year, Niakhar, Senegal, 1984–1996. Figure reproduced with permission from
Preziosi et al [2].
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Coverage of 3 doses of pentavalent vaccine by 12 months of age
was 94% in 2014. In this collection of samples, which was col-
lected and stored between 2005 and 2012, 77% of the cohort had
received at least 3 doses of DPT prior to sampling. Our results
showed that 6% of individuals had antibody concentrations
≥62.5 EU/mL, which is indicative of a recent pertussis infection
(Figures 2 and 3).
Unfortunately, no stored samples were available from chil-
dren aged <2 years, hence we cannot comment on evidence of
responses to either vaccination or environmental exposure in
infants and children aged <2 years. We also analyzed a small
set of 30 cord blood samples for PTx antibody titers and saw
no evidence of recent exposure of pregnant women, as all titers
were below 20 EU/mL (B. Kampmann, unpublished data).
These data are consistent with ﬁndings in Thailand [7] and Swe-
den [8], which also did not show evidence of recent infection in
pregnant women based on PTx antibody levels. To extend the
available dataset relating to women of childbearing age as a pos-
sible source of infection in infants, a larger evaluation of PTx in
stored cord blood samples could be undertaken relatively easily
as a proxy. However, our age-related longitudinal data present-
ed above do not indicate that there is a particular peak in anti-
body titers that is suggestive of recent infection in this age
group, possibly because of ongoing protection via the whole
cell vaccine received in childhood. This hypothesis could be
tested in a comparable cohort of women who were immunized
with acellular pertussis vaccine in childhood. However, this is
not the case in West Africa, and differences in epidemiological
background might play a role in the interpretation of such com-
parative studies.
A relatively recent seroepidemiological study included 402
children aged between 1 and 9 years from 5 villages in northern
Senegal for longitudinal measurements of the IgG response to PTx
over a 15-month period, during which 5 blood samples were col-
lected from each child at regular intervals [9]. More than 85% of
the cohort had documented evidence of having received at least 1
dose of diptheria, tetanus and whole cell pertussis; however, vac-
cination coverage differed between the sites, correlating with the
antibody titers measured. A total of 33.6% of the global cohort
presented anti-PTx IgG concentrations higher than 30 IU/mL
and 16.2% higher than 80 IU/mL. In this study, circulation of
B. pertussis was clearly shown by serological measurement, with
great variation in serological responses to PTx antigens according
to age and village of residence. However, the authors did not
report cases of pertussis disease among this cohort.
OPPORTUNITIES TO GATHER DATA FROM EXISTING
PNEUMONIA SURVEILLANCE PLATFORMS AND
DEMOGRAPHIC HEALTH SURVEILLANCE SYSTEMS
In the absence of a dedicated pertussis surveillance platform,
data from other ﬁeld activities might be informative. The best
data on vaccination and serious infections in infancy in our re-
gion are from the Basse Health & Demographic Surveillance
System (BHDSS) in the rural east section of the Gambia [10].
The surveillance area encompasses a geographic area of 1111
km2, with a total population of 180 168 at the end of 2015
Figure 2. Concentrations of pertussis toxin (PTx) immunoglobulin G by age group for those with vaccination records (born after 1 January 1996), 2008 serosurvey in Keneba
and Manduar, West Kiang region, the Gambia. Numbers on top of bars are total number sampled by age group. Reproduced with permission from Scott et al [4].
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and 6475 infants aged 0–11 months. The EPI in the Gambia in-
cludes a whole cell pertussis antigen as part of the pentavalent
vaccine (hepatitis B, H. inﬂuenzae type b, DPT). In the BHDSS,
coverage of 3 doses of pentavalent vaccine by age 12 months was
94% in 2014. Verbal autopsies (a research method that helps to
determine probable causes of death in cases without medical
records or formal medical examination) are performed for all
deaths in the BHDSS, which are interpreted using the Inter-
VA algorithm (interva.net). Diagnosis of pertussis using the
Inter-VA algorithm has not been validated.
Population-based surveillance for suspected meningitis, sep-
sis, and pneumonia in individuals aged ≥2 months has been
underway since 2008 [11]. The sensitive inclusion criteria
would include children with clinical disease due to pertussis in-
fection. Standardized identiﬁcation and investigation of patients
includes blood culture, chest radiograph, lumbar puncture, and
other sterile site samples. Nasopharyngeal swabs (NPS) have
been collected from all patients who met surveillance criteria
since 2015. The meningitis, sepsis, and pneumonia surveillance
system was expanded in 2012 to investigate by blood culture all
children aged <5 years who were admitted to health facilities in
the BHDSS. The BHDSS surveillance for invasive bacterial dis-
ease in pediatric admissions and meningitis, sepsis, and pneu-
monia in patients aged ≥2 months is ongoing in 2016.
Child mortality in the BHDSS is substantial, with 60–70 per
1000 live births; there were 367 deaths in infancy in 2014/2015
and 137 deaths occurred in health facilities. However, the sur-
veillance system described above was not designed to detect
cases of infection due to B. pertussis. Microbiological investiga-
tions are focused on common invasive bacterial pathogens, with
an aim to determine the impact of the introduction of pneumo-
coccal conjugate vaccine. NPSs are primarily investigated for
pneumococcal carriage. Laboratory investigations currently
available on site do not include speciﬁc PCR for the detection
of B. pertussis or Bordetella parapertussis.
Clinical ﬁndings are recorded for all patients who meet sur-
veillance criteria. Clinical diagnoses that may overlap with per-
tussis infection in children aged 0–23 months include a
clinician’s diagnosis of pertussis, whooping cough, croup, and
apnea in infants aged <2 months. The surveillance system en-
rolled 13 192 children aged 0–23 months from 12 May 2008
to 31 October 2015. The reported diagnoses included pertussis
in 4 cases, croup in 6, and apnea in 3. Thus, there is little clinical
evidence of signiﬁcant pertussis transmission in this population.
DATA FROM THE GAMBIA SITE OF THE PNEUMONIA
ETIOLOGY RESEARCH FOR CHILD HEALTH PROJECT
Despite the BHDSS surveillance system’s lack of speciﬁc diag-
nosis for pertussis, some laboratory data are available from
that location. The Pneumonia Etiology Research for Child
Health (PERCH) project was located in the BHDSS in 2012–
2013. Approximately 650 children aged 1–59 months with
acute cough and either chest wall indrawing or clinical danger
signs were investigated. This case deﬁnition may overlap with
that of pertussis infection. Children were investigated using na-
sopharyngeal and oropharyngeal swabs, which were analyzed
Figure 3. Concentrations of pertussis toxin (PTx) immunoglobulin G by age group for those without vaccination records (born after 1 January 1996), 2008 serosurvey in Keneba
and Manduar, West Kiang region, the Gambia. Numbers on top of bars are total number sampled by age group. Figure reproduced with permission from Scott et al [4].
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using a multiplex real-time PCR assay that included B. pertussis.
(For full details of the PERCH study, see article by Kate O′Brian
in this supplement.) In the 2 years of enrollment for PERCH in
the Gambia, pertussis was detected in 3 cases using this assay.
These data indicate that pertussis is not a common cause of
clinical pneumonia in our setting.
CURRENT DATA FROM HOSPITALIZED CHILDREN IN
THE GAMBIA AND SENEGAL
A recently published audit of morbidity and mortality in neo-
nates in the main teaching hospital in the Gambia reported
morbidity and mortality of nearly 5000 neonates admitted dur-
ing a 5-year period to assess outcome [12].
Of the 4944 admissions between 1 January 2010 and 31 De-
cember 2013, 1734 infants (35%) died, with 57% of all deaths
occurring within the ﬁrst 48 hours of admission. Possible severe
bacterial infection accounted for 44% (2166/4944) of admis-
sions, prematurity/low birthweight for 27% (1340/4944), and
intrapartum-related conditions for 20%. Pertussis was not re-
corded as a cause of death in any of the cases; however, inves-
tigations to ascertain causative organisms in any of the neonates
were minimal. Although this represents a comprehensive data-
set, the question of whether pertussis contributed to morbidity
or mortality in these infants in the neonatal period cannot be
answered conclusively.
Considering evidence of pertussis disease beyond the borders
of the Gambia, we have worked with colleagues at Centre Hos-
pitalier Régional Kaolack in central Senegal. After the capital
city Dakar, Kaolack is the second largest city in Senegal. The re-
gional hospital is a referral center for central Senegal, offering a
range of specialty services. In 2014, 2932 children were admitted
to pediatric services and 3873 were admitted in 2015. The clin-
ical severity of admitted cases is high, with 1298 (19%) deaths
recorded among children admitted in 2014 and 2015. A signiﬁ-
cant proportion of pediatric admissions are in the neonatal period
(24%, 1602/6805). Of all pediatric deaths, 21% (278/1298) oc-
curred in the neonatal period with prematurity (n = 127), asphyx-
ia (n = 79), and infection (n = 72) the predominant causes of
mortality. Of all pediatric admissions in Kaolack, 14% are associ-
ated with malnutrition, 9% are due to acute respiratory infections,
8% malaria, 7% diarrhea, and 24% of neonatal admissions are as-
sociated with infection. Pertussis is an uncommon diagnosis, with
little evidence that it plays a signiﬁcant role in the burden of ill-
ness in childhood (Dr B. Mbodj, personal communication).
SO, IS PERTUSSIS A SIGNIFICANT PATHOGEN IN
WEST AFRICA?
In order to answer the question of whether pertussis is a signiﬁ-
cant pathogen in the Gambia and Senegal, one must consider
possible reasons for cases being missed and the likelihood of
these scenarios. The primary reason that our data may miss
cases of pertussis is that many children with acute illness do
not present to health facilities. A secondary reason is clinical
misdiagnosis of cases of pertussis as an alternative respiratory
illness such as bronchopneumonia, bronchiolitis, or other
lower respiratory tract infections, which is a common problem.
In a recent publication from South Africa [13], up to 90% of
pertussis cases were assigned an alternative diagnosis. Despite
reasonable immunization coverage by age 12 months in our set-
ting, delayed immunization is common, and cases of pertussis
may follow the usual epidemiology, with cases occurring before
vaccine-induced protection is achieved.
However, the clinical experiences in Basse and Kaolack sug-
gest that pertussis is quite uncommon in infants presenting to
health facilities. The clinicians in both settings are experienced
pediatricians who would be expected to detect the classic fea-
tures of whooping cough. Misdiagnosis seems unlikely as atyp-
ical cases of pertussis in infancy are unlikely in the absence of
signiﬁcant numbers of typical cases. More likely than misdiag-
nosis, it seems that cases of pertussis may be missed among in-
fants who do not present to health facilities. However, in our
experience, childhood deaths at home often follow an initial
presentation to health facilities. In the BHDSS, 44% of neonatal
deaths occur at home without a speciﬁc diagnosis. Thus, in
Basse and Kaolack, it is possible that the paucity of pertussis
cases may relate to children not presenting to health facilities.
Despite our clinical experience, due to the lack of systematic
and targeted surveillance with laboratory conﬁrmation of
B. pertussis infection, we cannot deﬁnitively conclude that per-
tussis disease is well controlled in West Africa.
SUGGESTED INTERVENTIONS TO CONCLUDE ON
THE BURDEN OF PERTUSSIS IN WEST AFRICA
To provide certain resolution to the question of whether there is
signiﬁcant transmission of pertussis in our setting, 2 relatively
simple surveillance techniques could be added to our current
procedures. First, for a period of 2 years, an NPS could be
taken from every child aged <12 months admitted to medical
facilities in Basse and Kaolack with cough as a presenting symp-
tom. Induced sputum appears to have a slightly higher yield to
detect the pathogen, either on its own or in combination with
NPS [13].However, in the context of larger surveillance studies,
this is less practical. Second, active surveillance could be con-
ducted in 2 or 3 easily accessible urban areas with variable vac-
cination coverage or, more speciﬁcally, varied delay in the
receipt of EPI vaccines. Suitable urban areas include Basse (me-
dium/high vaccine coverage), Kaolack (medium vaccine cover-
age), and 1 other more isolated setting with more modest
vaccine coverage, as available from our DSS data. Samples
would need to be processed using a sensitive PCR assay, opti-
mized for the detection of B. pertussis or B. parapertussis,
since culture methods are known to lack sensitivity [14]. If per-
tussis transmission was found to be signiﬁcant and these sur-
veillance measures were taken, one would expect to detect
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substantial numbers of laboratory-conﬁrmed cases. If these rel-
atively intense surveillance measures failed to detect signiﬁcant
numbers of pertussis cases, one would conclude that good dis-
ease control has been achieved.
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